Alzheimer’s disease
-
PublishedAugust 2, 2022
Even simple exercise may help aging brain, study hints
Stretching and balancing moves can be as beneficial as an aerobic workout.
-
PublishedApril 16, 2022
Commentary: Medicare is cleaning up FDA’s mess on Biogen’s Alzheimer’s drug
By clarifying what evidence it needs before it will pay for medicines like Aduhelm, the agency paved the way for improved drug innovation.
-
PublishedApril 5, 2022
Cumberland woman running Boston Marathon for those with Alzheimer’s
Jackie Mundry's beloved grandmother was diagnosed with dementia and Mundry's marathon team is raising funds to benefit the national Alzheimer's Association.
-
PublishedNovember 19, 2021
Commentary: Focus on hearing aids, not a questionable Alzheimer’s drug
Alzheimer’s groups will help far more people by promoting hearing aids and a healthy lifestyle than by touting Aduhelm.
-
PublishedNovember 13, 2021
Commentary: The next hospital crisis is coming. Let’s hope the U.S. is prepared
Response teams that respect and protect patients and care providers are one essential solution for behavioral emergencies among people with dementia.
-
PublishedJuly 29, 2021
Research looks for possible COVID-19 link to later Alzheimer’s
Experts stress far more research is needed – and getting underway – to tell if COVID-19 might raise the risk of Alzheimer's or other brain problems later in life, or if people eventually recover from 'brain fog.'
-
PublishedJuly 13, 2021
Medicare evaluating coverage for $56,000 Alzheimer’s drug
Although pricey drugs are now fairly commonplace, the recent approval of Aduhelm prompted an unusually intense backlash.
-
PublishedJuly 9, 2021
FDA chief calls for investigation into review of controversial new Alzheimer’s drug
It's the latest fallout over last month's approval of Aduhelm, an expensive and unproven therapy that the agency OK'd against the advice of its own outside experts.
-
PublishedJuly 8, 2021
FDA reverses itself under pressure, moves to limit use of new Alzheimer’s drug
The Food and Drug Administration says the change is intended to address confusion among physicians and patients about who should get Aduhelm, which has faced an intense public backlash since its approval last month.
-
PublishedJuly 2, 2021
Commentary: The Alzheimer’s mistake by the FDA is already getting worse
Now drugmaker Eli Lilly is pushing forward with another unproven treatment on the basis of limited evidence.